The value of positron emission tomography for monitoring response to radiotherapy in head and neck cancer

Molecular Imaging and Biology

Volumn 5, Issue 4, 2003, Pages 257-270

  Klabbers, Bianca M ^a   Lammertsma, Adriaan A ^a   Slotman, Ben J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

2 deoxy 2 18F fluoro D glucose; Head and Neck; Positron emission tomography; Radiotherapy; Response monitoring

Indexed keywords

FLUORODEOXYGLUCOSE F 18; PROPANOL; RADIOPHARMACEUTICAL AGENT; SEMICARBAZONE DERIVATIVE; TRACER;

CANCER RADIOTHERAPY; CANCER SCINTISCANNING; CANCER STAGING; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DRUG UPTAKE; HEAD AND NECK CANCER; HUMAN; METHODOLOGY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE DIAGNOSIS; RETROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME;

EID: 0043288075     PISSN: 15361632     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1536-1632(03)00102-1     Document Type: Article

References (100)

1. 18-FDG positron emission tomography (PET)] Laryngorhinootologie 79 2000 201-206
2. Rigo P. Paulus P. Kaschten B.J. et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose Eur. J. Nucl. Med. 23 1996 1641-1674
3. Wong W.L. Chevretton E.B. McGurk M. et al. A prospective study of PET-FDG imaging for the assessment of head and neck squamous cell carcinoma Clin. Otolaryngol. 22 1997 209-214
4. Shreve P.D. Anzai Y. Wahl R.L. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants Radiographics 19 1999 61-77 quiz 150-151
5. 18F-fluoro-2-deoxy-D-glucose positron emission tomography Laryngoscope 109 1999 970-975
6. Sugawara Y. Braun D.K. Kison P.V. et al. Rapid detection of human infections with fluorine-18 fluorodeoxyglucose and positron emission tomography: preliminary results Eur. J. Nucl. Med. 25 1998 1238-1243
7. 18F- fluorodeoxyglucose in detecting residual/recurrent squamous cell carcinoma of the head and neck AJNR Am. J. Neuroradiol. 19 1998 1189-1196
8. 18F-FDG PET: a comparison with conventional methods Eur. J. Nucl. Med. 28 2001 816-821
9. Strauss L.G. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients Eur. J. Nucl. Med. 23 1996 1409-1415
10. Stokkel M.P. Bongers V. Hordijk G.J. van Rijk P.P. FDG positron emission tomography in head and neck cancer: pitfall or pathology? Clin. Nucl. Med. 24 1999 950-954
11. Macapinlac H.A. Larson S.M. Positron emission tomography (PET)-measured biochemical response to radiotherapy of laryngeal tumors Cancer J. Sci. Am. 3 1997 333-335
12. Engel H. Steinert H. Buck A. et al. Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations J. Nucl. Med. 37 1996 441-446
13. Jabour B.A. Choi Y. Hoh C.K. et al. Extracranial head and neck: PET imaging with 2-[F-18]fluoro-2-deoxy-D-glucose and MR imaging correlation Radiology 186 1993 27-35
14. Kubota K. Kubota R. Yamada S. FDG accumulation in tumor tissue J. Nucl. Med. 34 1993 419-421
15. 18F)-FDG positron emission tomography after neoadjuvant radiation treatment of mouth carcinoma] Strahlenther. Onkol. 177 2001 145-152
16. Kubota R. Yamada S. Kubota K. et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography J. Nucl. Med. 33 1992 1972-1980
17. Haberkorn U. Strauss L.G. Reisser C. et al. Glucose uptake, perfusion, and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry J. Nucl. Med. 32 1991 1548-1555
18. Jacob R. Welkoborsky H.J. Mann W.J. Jauch M. Amedee R. [Fluorine-18]fluorodeoxyglucose positron emission tomography, DNA ploidy and growth fraction in squamous-cell carcinomas of the head and neck ORL J. Otorhinolaryngol. Relat. Spec. 63 2001 307-313
19. Minn H. Joensuu H. Ahonen A. Klemi P. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors Cancer 61 1988 1776-1781
20. Minn H. Paul R. Ahonen A. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose J. Nucl. Med. 29 1988 1521-1525
21. Bailet J.W. Abemayor E. Jabour B.A. et al. Positron emission tomography: a new, precise imaging modality for detection of primary head and neck tumors and assessment of cervical adenopathy Laryngoscope 102 1992 281-288
22. Lapela M. Grenman R. Kurki T. et al. Head and neck cancer: detection of recurrence with PET and 2-[F-18]fluoro-2-deoxy-D-glucose Radiology 197 1995 205-211
23. Zeitouni A.G. Yamamoto Y.L. Black M. Gjedde A. Functional imaging of head and neck tumors using positron emission tomography J. Otolaryngol. 23 1994 77-80
24. 18FDG in patients with bronchogenic carcinoma Chest 108 1995 1617-1621
25. Jacob R. Welkoborsky H.J. Mann W.J. et al. Heterogeneity of squamous cell carcinomas of the head and neck-analysis of tumor biologic factors and proliferation rates Laryngoscope 106 1996 1170-1175
26. 18F-FDG) in head and neck cancer J. Laryngol. Otol. 113 1999 548-554
27. Halfpenny W. Hain S.F. Biassoni L. et al. FDG-PET. A possible prognostic factor in head and neck cancer Br. J. Cancer 86 2002 512-516
28. Smith T.A. Titley J. Deoxyglucose uptake by a head and neck squamous carcinoma: influence of changes in proliferative fraction Int. J. Radiat. Oncol. Biol. Phys. 47 2000 219-223
29. Hoffman E.J. Huang S.C. Phelps M.E. Quantitation in positron emission computed tomography:: 1. Effect of object size: J. Comput. Assist. Tomogr. 3 1979 299-308
30. Greven K.M. Williams D.W.3rd Keyes J.W.Jr. et al. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation Cancer 74 1994 1355-1359
31. Greven K.M. Williams D.W. 3rd McGuirt W.F. Sr. et al. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer Head Neck 23 2001 942-946
32. Terhaard C.H. Bongers V. van Rijk P.P. Hordijk G.J. F-18-fluoro-deoxy-glucose positron-emission tomography scanning in detection of local recurrence after radiotherapy for laryngeal/pharyngeal cancer Head Neck 23 2001 933-941
33. 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma J. Nucl. Med. 44 2003 198-206
34. Stokkel M.P. Terhaard C.H. Hordijk G.J. van Rijk P.P. The detection of local recurrent head and neck cancer with fluorine-18 fluorodeoxyglucose dual-head positron emission tomography Eur. J. Nucl. Med. 26 1999 767-773
35. 18F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma J. Clin. Oncol. 20 2002 4199-4208
36. Sakamoto H. Nakai Y. Ohashi Y et al. Monitoring of response to radiotherapy with fluorine-18 deoxyglucose PET of head and neck squamous cell carcinomas Acta Otolaryngol. Suppl. 538 1998 254-260
37. Lowe V.J. Boyd J.H. Dunphy F.R. et al. Surveillance for recurrent head and neck cancer using positron emission tomography J. Clin. Oncol. 18 2000 651-658
38. 18FDG-PET for the assessment of primary head and neck tumors: clinical, computed tomography, and histopathological correlation in 38 patients Laryngoscope 108 1998 1578-1583
39. Brucher B.L. Weber W. Bauer M. et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography Ann. Surg. 233 2001 300-309
40. Rege S. Maass A. Chaiken L. et al. Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers Cancer 73 1994 3047-3058
41. Hanasono M.M. Kunda L.D. Segall G.M. Ku G.H. Terris D.J. Uses and limitations of FDG positron emission tomography in patients with head and neck cancer Laryngoscope 109 1999 880-885
42. Lapela M. Eigtved A. Jyrkkio S. et al. Experience in qualitative and quantitative FDG PET in follow-up of patients with suspected recurrence from head and neck cancer Eur. J. Cancer 36 2000 858-867
43. Pai M. Park C.H. Suh J.H. Koh J.H. Fluorine-18 fluorodeoxyglucose imaging using dual-head coincidence positron emission tomography without attenuation correction in patients with head and neck cancer Clin. Nucl. Med. 24 1999 495-500
44. Hermans R. Pameijer F.A. Mancuso A.A. Parsons J.T. Mendenhall W.M. Laryngeal or hypopharyngeal squamous cell carcinoma: can follow-up CT after definitive radiation therapy be used to detect local failure earlier than clinical examination alone? Radiology 214 2000 683-687
45. Kao C.H. Shiau Y.C. Shen Y.Y. Yen R.F. Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with technetium-99m methoxyisobutylisonitrile single photon emission computed tomography and computed tomography: comparison with 18-fluoro-2-deoxyglucose positron emission tomography Cancer 94 2002 1981-1986
46. Li P. Zhuang H. Mozley P.D. et al.. Evaluation of recurrent squamous cell carcinoma of the head and neck with FDG positron emission tomography Clin. Nucl. Med. 26 2001 131-135
47. Hubner K.F. Thie J.A. Smith G.T. et al. Clinical utility of FDG-PET in detecting head and neck tumors. A comparison of diagnostic methods and modalities Clin. Positron Imaging 3 2000 7-16
48. Anzai Y. Carroll W.R. Quint D.J. et al. Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-[F-18]fluoro-D-glucose PET and MR imaging diagnoses Radiology 200 1996 135-141
49. 18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods Eur. J. Nucl. Med. 27 2000 731-743
50. 18FDG uptake in soft tissue masses Eur. J. Nucl. Med. 26 1999 22-30
51. Kim C.K. Gupta N.C. Chandramouli B. Alavi A. Standardized uptake values of FDG: body surface area correction is preferable to body weight correction J. Nucl. Med. 35 1994 164-167
52. Kim C.K. Gupta N.C. Dependency of standardized uptake values of fluorine-18 fluorodeoxyglucose on body size: comparison of body surface area correction and lean body mass correction Nucl. Med. Commun. 17 1996 890-894
53. Schomburg A. Bender H. Reichel C. et al. Standardized uptake values of fluorine-18 fluorodeoxyglucose: the value of different normalization procedures Eur. J. Nucl. Med. 23 1996 571-574
54. Lindholm P. Minn H. Leskinen-Kallio S. et al. Influence of the blood glucose concentration on FDG uptake in cancer-a PET study J. Nucl. Med. 34 1993 1-6
55. 18f]fluoro-D-glucose Mol. Imaging Biol. 4 2002 171-178
56. 18FDG uptake in breast cancer during chemotherapy: comparison of analytical methods Eur. J. Nucl. Med. Mol. Imaging 30 2003 674-681
57. Hunter G.J. Hamberg L.M. Alpert N.M. Choi N.C. Fischman A.J. Simplified measurement of deoxyglucose utilization rate J. Nucl. Med. 37 1996 950-955
58. Sokoloff L. Reivich M. Kennedy C. et al. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat J. Neurochem. 28 1977 897-916
59. Patlak C.S. Blasberg R.G. Fenstermacher J.D. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data J. Cereb. Blood Flow Metab. 3 1983 1-7
60. Thie J.A. Hubner K.F. Smith G.T. Optimizing imaging time for improved performance in oncology PET studies Mol. Imaging Biol. 4 2002 238-244
61. Keyes J.W.Jr. SUV: standard uptake or silly useless value? J. Nucl. Med. 36 1995 1836-1839
62. Weber W.A. Ziegler S.I. Thodtmann R. Hanauske A.R. Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET J. Nucl. Med. 40 1999 1771-1777
63. Weber W.A. Schwaiger M. Avril N. Quantitative assessment of tumor metabolism using FDG-PET imaging Nucl. Med. Biol. 27 2000 683-687
64. Minn H. Zasadny K.R. Quint L.E. Wahl R.L. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET Radiology 196 1995 167-173
65. 18F-FDG PET J. Nucl. Med. 43 2002 1304-1309
66. Fujibayashi Y. Waki A. Sakahara H. et al. Transient increase in glycolytic metabolism in cultured tumor cells immediately after exposure to ionizing radiation: from gene expression to deoxyglucose uptake Radiat. Res. 147 1997 729-734
67. Minn H. Lapela M. Klemi P.J. et al. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer J. Nucl. Med. 38 1997 1907-1911
68. 18FDG PET Acta Oncol. 36 1997 741-747
69. Kitagawa Y. Sadato N. Azuma H. et al. FDG PET to evaluate combined intra-arterial chemotherapy and radiotherapy of head and neck neoplasms J. Nucl. Med. 40 1999 1132-1137
70. Kitagawa Y. Sano K. Nishizawa S. et al. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer Eur. J. Nucl. Med. Mol. Imaging 30 2003 63-71
71. 18F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy J. Clin. Oncol. 20 2002 1398-1404
72. Ichiya Y. Kuwabara Y. Otsuka M. et al. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography J. Nucl. Med. 32 1991 1655-1660
73. Rege S. Safa A.A. Chaiken L. et al. Positron emission tomography: an independent indicator of radiocurability in head and neck carcinomas Am. J. Clin. Oncol. 23 2000 164-169
74. Berlangieri S.U. Brizel D.M. Scher R.L. et al. Pilot study of positron emission tomography in patients with advanced head and neck cancer receiving radiotherapy and chemotherapy Head Neck 16 1994 340-346
75. Brun E. Kjellen E. Tennvall J. et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma Head Neck 24 2002 127-135
76. Rege S.D. Chaiken L. Hoh C.K. et al. Change induced by radiation therapy in FDG uptake in normal and malignant structures of the head and neck: quantitation with, PET Radiology 189 1993 807-812
77. Chaiken L. Rege S. Hoh C. et al. Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy Int. J. Radiat. Oncol. Biol. Phys. 27 1993 455-464
78. Nordsmark M. Overgaard M. Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck Radiother. Oncol. 41 1996 31-39
79. Nordsmark M. Overgaard J. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy Radiother. Oncol. 57 2000 39-43
80. Nunn A. Linder K. Strauss H.W. Nitroimidazoles and imaging hypoxia Eur. J. Nucl. Med. 22 1995 265-280
81. Rischin D. Peters L. Hicks R. et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer J. Clin. Oncol. 19 2001 535-542
82. 18F]fluoromisonidazole: apretherapy study of 37 patients Int. J. Radiat. Oncol. Biol. Phys. 36 1996 417-428
83. Koh W.J. Rasey J.S. Evans M.L. et al. Imaging of hypoxia in human tumors with [F-18]Fluoromisonidazole Int. J. Radiat. Oncol. Biol. Phys. 22 1992 199-212
84. 4-methylthiosemicarbazone): an agent for radiotherapy Proc. Natl. Acad. Sci. USA 98 2001 1206-1211
85. Lewis J.S. McCarthy D.W. McCarthy T.J. Fujibayashi Y. Welch M.J. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model J. Nucl. Med. 40 1999 177-183
86. Chao K.S. Bosch W.R. Mutic S. et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy Int. J. Radiat. Oncol. Biol. Phys. 49 2001 1171-1182
87. de Wolde H. Pruim J. Mastik M.F. Koudstaal J. Molenaar W.M. Proliferative activity in human brain tumors: comparison of histopathology and L-[1-(11)C]tyrosine, PET J. Nucl. Med. 38 1997 1369-1374
88. 11C]methionine-positron emission tomography Radiother. Oncol. 52 1999 225-232
89. 11C]methionine Int. J. Radiat. Oncol. Biol. Phys. 30 1994 1195-1199
90. Kubota K. Ishiwata K. Kubota R. et al. Tracer feasibility for monitoring tumor radiotherapy: a quadruple tracer study with fluorine-18-fluorodeoxyglucose or fluorine-18-fluorodeoxyuridine, L-[methyl-14C]methionine, [6-3H]thymidine, and gallium-67 J. Nucl. Med. 32 1991 2118-2123
91. Minn H. Clavo A.C. Grenman R. Wahl R.L. In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous-cell carcinoma of the head and neck J. Nucl. Med. 36 1995 252-258
92. Lindholm P. Leskinen-Kallio S. Minn H. et al. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine in head and neck cancer J. Nucl. Med. 34 1993 1711-1716
93. 11C]methionine Int. J. Radiat. Oncol. Biol. Phys. 32 1995 787-794
94. Shields A.F. Mankoff D.A. Link J.M. et al. Carbon-11-thymidine and FDG to measure therapy response J. Nucl. Med. 39 1998 1757-1762
95. Shields A.F. Grierson J.R. Dohmen B.M. et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography Nat. Med. 4 1998 1334-1336
96. Kong X.B. Zhu Q.Y. Vidal P.M. et al. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro- 3′-deoxythymidine and 3′-azido-3′-deoxythymidine Antimicrob. Agents Chemother. 36 1992 808-818
97. 18F]FLT for imaging of cellular proliferation in vivo Nucl. Med. Biol. 27 2000 143-156
98. Sherley J.L. Kelly T.J. Regulation of human thymidine kinase during the cell cycle J. Biol. Chem. 263 1988 8350-8358
99. Munch-Petersen B. Cloos L. Tyrsted G. Eriksson S. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides J. Biol. Chem. 266 1991 9032-9038
100. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group Eur. J. Cancer 35 1999 1773-1782